IJTLD open最新文献_第8页

Accuracy of Truenat™ MTB Plus for the diagnosis of pulmonary TB. Truenat™MTB Plus诊断肺结核的准确性

IJTLD open Pub Date : 2025-04-09 eCollection Date: 2025-04-01 DOI: 10.5588/ijtldopen.24.0561

M C M Melo, A K Silveira, A P R Dalvi, J Silva, V S Printes, L Anselmo, T I da Silva, M M Oliveira, C Conceição, A Lopes, V Bollela, M Cordeiro-Santos, M Bhering, A S R Moreira, A C C Carvalho, A L Kritski

{"title":"Accuracy of Truenat™ MTB Plus for the diagnosis of pulmonary TB.","authors":"M C M Melo, A K Silveira, A P R Dalvi, J Silva, V S Printes, L Anselmo, T I da Silva, M M Oliveira, C Conceição, A Lopes, V Bollela, M Cordeiro-Santos, M Bhering, A S R Moreira, A C C Carvalho, A L Kritski","doi":"10.5588/ijtldopen.24.0561","DOIUrl":"https://doi.org/10.5588/ijtldopen.24.0561","url":null,"abstract":"Background: Truenat™ is a WHO-recommended rapid molecular test for diagnosing TB and detecting rifampicin resistance, whose performance has been evaluated in a few high TB burden countries.Methods: A prospective multicentre study was conducted in Brazil to estimate the sensitivity and specificity of Truenat MTB Plus compared to Xpert® MTB/RIF Ultra for detecting pulmonary TB. Liquid culture for Mycobacterium tuberculosis and drug susceptibility testing were used as reference.Results: Among 283 participants, 112 (39.6%) had culture-positive pulmonary TB. The sensitivity and specificity of Truenat MTB Plus were respectively 72.7% (95% CI 63.41-80.78) and 99.4% (95% CI 96.71-99.98), compared to 78.4% (95% CI 69.56-85.63) and 99.4% (95% CI 96.67-99.98) for Xpert MTB/RIF Ultra. In 89 people living with HIV (PLHIV), Truenat MTB Plus showed a sensitivity of 45.0% (95% CI 23.06-68.47) and specificity of 100.0% (95% CI 95.64-100.00). Among 71 patients previously treated for TB, Truenat MTB Plus showed sensitivity and specificity of respectively 79.3% (95% CI 60.28-92.01) and 97.5% (95% CI 86.84-99.94). Xpert MTB/RIF Ultra detected rifampicin resistance in 11/88 samples (12.5%) vs 9/72 (12.5%) with Truenat MTB Plus.Conclusion: The Truenat MTB Plus performance was comparable to Xpert MTB/RIF Ultra. Both tests demonstrated lower sensitivity in PLHIV.","PeriodicalId":519984,"journal":{"name":"IJTLD open","volume":"2 4","pages":"199-207"},"PeriodicalIF":0.0,"publicationDate":"2025-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11984528/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144052493","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prevalence and risk factors of COVID-19 co-infection in TB patients. 结核病患者合并感染COVID-19的流行情况及危险因素

IJTLD open Pub Date : 2025-04-09 eCollection Date: 2025-04-01 DOI: 10.5588/ijtldopen.25.0016

T Nyamsaikhan, G Dorj, O Erdenee, B Jantsansengee, B Badamnachin, G Ochirdorj

引用次数: 0

Costs and cost-effectiveness of integrated screening for non-communicable diseases in TB contacts. 结核病接触者非传染性疾病综合筛查的成本和成本效益。

IJTLD open Pub Date : 2025-03-12 eCollection Date: 2025-03-01 DOI: 10.5588/ijtldopen.24.0625

Y Hamada, R Mukora, R Pelusa, T Ntshiqa, J Shedrawy, K Velen, I Abubakar, S Charalambous, S Walker, M X Rangaka

{"title":"Costs and cost-effectiveness of integrated screening for non-communicable diseases in TB contacts.","authors":"Y Hamada, R Mukora, R Pelusa, T Ntshiqa, J Shedrawy, K Velen, I Abubakar, S Charalambous, S Walker, M X Rangaka","doi":"10.5588/ijtldopen.24.0625","DOIUrl":"https://doi.org/10.5588/ijtldopen.24.0625","url":null,"abstract":"Background: Integrating non-communicable disease (NCD) screening into TB household contact investigations may identify undiagnosed NCDs and reduce the burden of both conditions. However, evidence on the costs and cost-effectiveness of this approach is limited.Method: We conducted a cross-sectional study in South Africa to assess patient and provider costs for NCD screening (hypertension, diabetes, chronic kidney disease, dyslipidaemia). Incremental costs per NCD case identified were calculated. Using a decision tree model, we estimated incremental costs per disability-adjusted life year (DALY) averted over 10 years from a healthcare perspective, with cardiovascular disease (CVD) risk estimated using the WHO prediction model.Results: The incremental cost was USD72.3 per contact screened and USD334.0 per NCD case identified. Integrated screening reduced mean 10-year CVD risk from 5.7% to 2.7% among contacts with NCDs. The incremental cost-effectiveness ratio (ICER) was USD27,043.6 per DALY averted, exceeding South Africa's threshold of USD3,708. Management of identified NCDs, mainly drug costs, comprised over 80% of total incremental costs. The ICER decreased in populations with a high risk for NCDs.Conclusion: Integrated NCD screening was not cost-effective, mainly due to subsequent care costs. Prioritising individuals at high risk for NCDs can improve cost-effectiveness.","PeriodicalId":519984,"journal":{"name":"IJTLD open","volume":"2 3","pages":"160-165"},"PeriodicalIF":0.0,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11906026/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143653258","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The risk of rifampicin-resistant TB after drug-susceptible TB treatment. 药物敏感结核治疗后出现利福平耐药结核的风险。

IJTLD open Pub Date : 2025-03-12 eCollection Date: 2025-03-01 DOI: 10.5588/ijtldopen.24.0552

A N Shapiro, H Moultrie, K R Jacobson, J Bor, P da Silva, L Scott, H E Jenkins

引用次数: 0

An open-label cluster-randomised trial on TB preventive therapy for children. 一项关于儿童结核病预防治疗的开放标签集群随机试验。

IJTLD open Pub Date : 2025-03-12 eCollection Date: 2025-03-01 DOI: 10.5588/ijtldopen.24.0467

G Lemvik, L Larsson, F Rudolf, J E Vejrum, M Sodemann, V F Gomes, C Wejse

{"title":"An open-label cluster-randomised trial on TB preventive therapy for children.","authors":"G Lemvik, L Larsson, F Rudolf, J E Vejrum, M Sodemann, V F Gomes, C Wejse","doi":"10.5588/ijtldopen.24.0467","DOIUrl":"https://doi.org/10.5588/ijtldopen.24.0467","url":null,"abstract":"Background: In a study on 9 months of isoniazid preventive therapy (IPT) in children in Guinea-Bissau, 76% of children exposed to TB at home completed 6 months of IPT. We aimed to test whether 4 months of rifampicin and isoniazid (RH) would improve adherence compared to 9 months of isoniazid (INH).Methods: We conducted an open-label cluster-randomised superiority study in children aged <15 years living with a TB case. Children were randomised by house to receive 4 months of RH or 9 months of INH. RH was given as a fixed-combination pill. The primary outcome was adherence, defined as taking >80% of prescribed dosages per month, assessed by pill count. Our aim was 3 months of RH or 6 months of INH.Results: A total of 752 children from 223 houses were included, 354 in the INH group and 398 in the RH group. Overall, 57% of the children took >80% of the prescribed pills. In the INH group, 68% completed 6 months of therapy, while 61% of the RH group completed 3 months (OR 1.32, 95% CI 0.90-1.95). The main reason for non-adherence in both groups was travel or relocation, accounting for 50% of missed doses.Conclusion: The shorter preventive therapy of 4 months of RH did not improve adherence in children in Guinea-Bissau. Travelling was the primary reason for non-adherence.","PeriodicalId":519984,"journal":{"name":"IJTLD open","volume":"2 3","pages":"120-128"},"PeriodicalIF":0.0,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11906030/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143653253","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Concurrent pulmonary TB and histoplasmosis in an HIV-negative patient with Evans Syndrome. 埃文斯综合征hiv阴性患者并发肺结核和组织胞浆菌病。

IJTLD open Pub Date : 2025-03-12 eCollection Date: 2025-03-01 DOI: 10.5588/ijtldopen.24.0607

T-W Kao, M-T Tsai, S-C Pan, C-C Shu, W-Y Liao, J-S Jerng

引用次数: 0

Non-sputum-based triage and confirmatory diagnostic tests for pediatric TB. 儿童结核病的非痰分诊和确证性诊断试验。

IJTLD open Pub Date : 2025-03-12 eCollection Date: 2025-03-01 DOI: 10.5588/ijtldopen.24.0484

A Drane, A Molkenthin, M Gassama, S Pouzol, P Vanhems, J Hoffmann

{"title":"Non-sputum-based triage and confirmatory diagnostic tests for pediatric TB.","authors":"A Drane, A Molkenthin, M Gassama, S Pouzol, P Vanhems, J Hoffmann","doi":"10.5588/ijtldopen.24.0484","DOIUrl":"https://doi.org/10.5588/ijtldopen.24.0484","url":null,"abstract":"Background: Non-sputum-based triage and confirmatory tests are essential for early TB detection and timely treatment in children.Methods: A mini-review was conducted from January 2022 to May 2024, evaluating five studies on non-sputum-based assays for childhood TB diagnosis. Both Microbiological and Clinical Reference Standards were used to assess diagnostic accuracy and triage potential.Results: Among the confirmatory tests, only the gastric aspiration test with cartridge-based nucleic acid amplification tests (CBNAAT) met the WHO Target Product Profile criteria. However, this method remains invasive and is not suitable for point-of-care testing. Urine testing by gas chromatography-mass spectrometry (GC/MS) or C-ELISA (BJ76/A194) demonstrated high performance but lacked point-of-care applicability in resource-limited settings. Stool testing with CBNAAT is a viable alternative with high specificity but low sensitivity. For triage, urine lipoarabinomannan tests and blood MTB-HR tests show promise based on specificity, practicality, cost, and turnaround time.Conclusion: This review highlights the performance of non-sputum-based assays for childhood TB and their potential as triage tools. While some other innovations show promise for the triage and/or diagnosis of TB in adults, further studies are needed to evaluate the performance of these tests in pediatric populations.","PeriodicalId":519984,"journal":{"name":"IJTLD open","volume":"2 3","pages":"153-159"},"PeriodicalIF":0.0,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11906028/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143652496","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Urgent request for pretomanid label expansion to align with WHO guidelines and improve treatment accessibility and efficacy. 紧急要求扩大普雷托马尼标签，以符合世卫组织指南并改善治疗可及性和疗效。

IJTLD open Pub Date : 2025-03-12 eCollection Date: 2025-03-01 DOI: 10.5588/ijtldopen.25.0152

L Kuksa, C Andrejak, B Haecker, G Bothamley, A Calcagno, D M Cirillo, R Duarte, R Fatima, G Ferlazzo, L Guglielmetti, G Günther, C Hewison, C R Horsburgh, T Jäger, Y Kalancha, R Otto-Knapp, K Kranzer, T Lillebaek, G Marks, K Middelkoop, I Motta, V Rabinova, P Sommerfeld, P Tattevin, C Lange

引用次数: 0

Acceptability of a 250 mg levofloxacin formulation in children receiving TB preventive treatment. 250mg左氧氟沙星制剂在接受结核病预防治疗的儿童中的可接受性。

IJTLD open Pub Date : 2025-03-12 eCollection Date: 2025-03-01 DOI: 10.5588/ijtldopen.24.0569

S E Purchase, J Brigden, J A Seddon, N A Martinson, L Fairlie, S Staples, A Poswa, T Duong, H S Schaaf, A C Hesseling

{"title":"Acceptability of a 250 mg levofloxacin formulation in children receiving TB preventive treatment.","authors":"S E Purchase, J Brigden, J A Seddon, N A Martinson, L Fairlie, S Staples, A Poswa, T Duong, H S Schaaf, A C Hesseling","doi":"10.5588/ijtldopen.24.0569","DOIUrl":"https://doi.org/10.5588/ijtldopen.24.0569","url":null,"abstract":"Background: Recent evidence indicates that levofloxacin (LFX) is effective in preventing TB in individuals exposed to multidrug-resistant TB (MDR-TB). Despite the need for pediatric formulations, the 250 mg adult LFX formulation is affordable and widely used for TB treatment and prevention in children.Methods: TB-CHAMP (Tuberculosis Child Multidrug-resistant Preventive Therapy ISRCTN92634082) was a trial of MDR-TB preventive treatment, comparing levofloxacin to placebo in children with MDR-TB exposure. Acceptability questionnaires were administered to caregivers at six timepoints during the 24-week treatment phase. Likert scales were used to grade 6 domains of acceptability, and a composite acceptability (CA) outcome was generated. Factors associated with acceptability were assessed using modified Poisson regression models to estimate risk ratios (RRs).Results: Overall, 922 children were randomised, 453 to LFX and 469 to placebo. By Week 8, 25.1% of children on LFX had poor CA versus 6.2% receiving placebo (Weeks 0-24: RR 3.43, 95% CI 2.69-4.37). Acceptability in the LFX arm improved from 36.8% poor CA at baseline to 12.9% at Week 24. Only 11.7% of children swallowing tablets whole/halved had poor CA outcomes at Week 8, compared to 34.4% swallowing crushed/softened tablets.Conclusion: LFX 250 mg tablets have reasonable acceptability and could be used as an alternative to dispersible formulations, especially in children able to swallow tablets.","PeriodicalId":519984,"journal":{"name":"IJTLD open","volume":"2 3","pages":"129-136"},"PeriodicalIF":0.0,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11906031/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143653252","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Investigating low uptake of tuberculin skin testing when integrated with active case-finding for TB. 调查结核菌素皮肤试验与结核病主动病例发现相结合时的低吸收率。

IJTLD open Pub Date : 2025-03-12 eCollection Date: 2025-03-01 DOI: 10.5588/ijtldopen.24.0667

T S Johnson, A Nalutaaya, P Biché, K Ndyabayunga, R Okura, I Mugabi, D Nantale, V Nakiiza, P J Kitonsa, E A Kendall, A Katamba, D W Dowdy

引用次数: 0